Conductive keratoplasty (CK) was approved by the US Food and Drug Administration in March 2004 for the correction of hyperopia ranging from +0.75 to +3.00 diopters (D) and 0.75 D or less of cylinder in patients older than 40 years.1 With CK, hyperopic correction is achieved through the use of a nonablative radiofrequency that shrinks corneal stromal collagen and steepens the central cornea. A keratoplast is used to apply 8 to 32 treatment spots at the 6-, 7-, or 8-mm optical zone.
Patients chosen for CK are carefully screened to avert ocular complications. We report the case of a patient with previously undiagnosed Sjögren syndrome who developed corneal perforation after CK.
A 52-year-old Chinese woman with uncorrected visual acuity of 20/25 OU and dry eyes with normal meibomian gland status underwent uncomplicated CK of the right eye because of hyperopia (16 spots at 7- and 8-mm optical zones) for planned monovision on March 14, 2005, in Hong Kong. One week later, her manifest refraction was −0.25 + 0.25 × 90, uncorrected vision was 20/20−2, and near vision was Jaeger 3. Postoperative inferior corneal punctate staining was treated with artificial tears.
On March 31, 2005, 2 areas of full-thickness corneal perforation at the nasal and temporal CK-treated spots with iris plugging had developed. Treatment with oral acetazolamide and ascorbic acid, as well as 1% atropine sulfate, was given and the eye was patched. On April 4, 2005, the patient was taken to the operating room and the temporal iris plug was freed; the nasal iris plug was not removed to enable vascularization of the cornea. Glue was applied and a bandage contact lens placed. Serologic testing results revealed that the patient was positive for antinuclear antibody (1:320; positive, >160) and had antibodies to SS-A and SS-B (immune status ratio, 4.6 and 4.7, respectively; positive, >1.2). The diagnosis of Sjögren syndrome was made; the patient was treated systemically with celecoxib and prednisone.
The patient came to the Stanford University Eye Center, Stanford, California, for consultation on June 24, 2005. On examination, her visual acuity was counting fingers OD and 20/20 OS. Slitlamp examination revealed a large plug of glue over the right central cornea with an overlying bandage contact lens. The infranasal cornea appeared thinned and vascularized at the area of previous perforation. Sixteen CK spots were seen. Penetrating keratoplasty was recommended (Figure).
Corneal perforation after conductive keratoplasty in a patient with previously undiagnosed Sjögren syndrome. Note conductive keratoplasty spots on the superior cornea and glue over the area of the corneal perforation.
To our knowledge, this is the first reported case of corneal perforation in a patient who underwent CK having undiagnosed Sjögren syndrome. Sjögren syndrome, a chronic autoimmune inflammatory disease of the exocrine glands, including the lacrimal gland, predisposes to cornea stromal degradation and thinning, ulceration, and perforation as a result of diminished tear secretion, corneal epithelial breakdown, and enzymatic degradation of collagen by inflammatory cells.2 Corneal stromal degradation and thinning can be the initial sign of primary Sjögren syndrome.3
In patients with chronic dry eye before CK, it is important to evaluate for Sjögren syndrome. Correct diagnosis before refractive surgery may identify patients who may not be appropriate candidates for CK and prevent unnecessary postoperative complications.
Correspondence: Dr Manche, Department of Ophthalmology, Stanford University School of Medicine, 900 Blake Wilbur Dr, Stanford, CA 94305 (Edward.firstname.lastname@example.org).
Financial Disclosure: None reported.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Ophthalmology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 5
Customize your page view by dragging & repositioning the boxes below.
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.